Study wrapper · #1157
Cardiovascular Outcomes in a SELECT-Like Obesity Cohort: Real-World Insights From the Swedish AROS Database.
Editor's note
This registry study does not test semaglutide directly; it maps how a real-world SELECT-like population actually fares, and the answer is worse than the trial suggested — older, more prior strokes, higher event rates despite extensive preventive medication. That higher baseline risk translates into an estimated number-needed-to-medicate of 35 to avert one major cardiovascular event, a favorable figure for population-level impact. A useful bridge between trial efficacy and real-world applicability, with the standard limits of applying a trial's relative effect to an observational cohort.
Plain-language abstract
Swedish researchers used national health registries to find about 9,700 people resembling the participants in the SELECT trial — adults with obesity and established heart disease but no diabetes. In the real world, these people had more than twice the risk of major cardiovascular events compared with the general population, and about 22% experienced one over 5.4 years of follow-up. Applying SELECT's semaglutide effect to these real-world risks, roughly 35 such people would need the drug for one major cardiovascular event to be avoided.